Poseida Therapeutics, Inc. (Nasdaq: PSTX), a US-based clinical-stage cell and gene therapy company, announced on Monday that it has named Syed Rizvi MD as its new chief medical officer, effective 1 April 2024.

Dr Rizvi, a seasoned executive, has more than 20 years of experience across all stages of drug development, which includes clinical strategy, execution, and commercialisation. He has recently served as chief medical officer of Caribou Biosciences, chief medical officer at Chimeric Therapeutics and global medical head of the CAR-T program at Celgene. He also served in global clinical leadership roles of increasing responsibility at Novartis, Merck, and Genta, Inc.

Kristin Yarema, Ph.D., Poseida president and chief executive officer, said, 'Syed brings to Poseida an impressive combination of industry leadership and highly specialised drug development experience in cell therapy, and I am excited to welcome him to our leadership team during this important period of execution across our clinical stage CAR-T portfolio. Syed has a proven track record in guiding the development and commercialisation of multiple cancer treatments, including three approved autologous CAR-T cell therapies, and his expertise will be an invaluable asset as we usher in the next wave of cell and gene therapies.'